All Stories

  1. Talking to the doctor reduces tics more than trying not to tic
  2. Correlating clinical course with baseline subcortical shape in provisional tic disorder
  3. Diagnostic Criteria for Primary Tic Disorders: More Reappraisal
  4. Tourette syndrome research highlights from 2023
  5. What's new with tics and Tourette's? Highlights from 2023.
  6. Tics that started recently usually get better but almost never go away completely.
  7. Tics in ADHD
  8. Tourette syndrome research highlights from 2022
  9. Door-To-Door Video-Enhanced Prevalence Study of Tourette Disorder Among African Americans
  10. Smoke gets in your tics
  11. Study protocol: A cross-sectional survey of clinicians to identify barriers to clinical practice guideline implementation in the assessment and treatment of persistent tic disorders
  12. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial
  13. Early‐Life and Family Risk Factors for Tic Disorder Persistence into Adulthood
  14. Tics in ADHD
  15. Finding reviewer suggestions for multi-author papers
  16. Functional tic-like presentations differ strikingly from Provisional Tic Disorder
  17. Editorial: Recent advances in understanding Tourette syndrome, tic disorders and functional tics
  18. Smoke gets in your tics
  19. Will people buzz their wrist in their daily life to help their tics?
  20. Testing whether median nerve stimulation helps tics by the mechanism we thought it did
  21. Tics in ADHD
  22. Suggestions for new NIH grant applicants
  23. Peripheral nerve induction of inhibitory brain circuits to treat Tourette syndrome: A randomized crossover trial
  24. Functional tic-like presentations differ strikingly from Provisional Tic Disorder
  25. TikTok Tourette’s: Are We Witnessing a Rise in Functional Tic-Like Behavior Driven by Adolescent Social Media Use?
  26. Tic prevalence by direct observation in an elementary school
  27. Tourette syndrome research highlights from 2021
  28. Diagnosis and Management of Functional Tic-Like Phenomena
  29. Door-to-door Video-Enhanced Prevalence Study of Tourette Disorder Among African Americans
  30. Why Tic Severity Changes from Then to Now and from Here to There
  31. 3.122 Open Trial of Median Nerve Stimulation for the Treatment of Tourette’s Disorder
  32. 13.2 Predictors of Tic Symptom Evolution After First Onset
  33. Functional tic-like presentations differ strikingly from Provisional Tic Disorder
  34. Median nerve stimulation for treatment of tics: A 4-week, open trial with ecological momentary assessment
  35. TikTok Tourette's: are we witnessing a rise in neurological conditions driven by adolescent social media use?
  36. Why tic severity changes from then to now and from here to there
  37. The start of the biggest brain imaging and genetics study ever in Tourette syndrome
  38. Finding reviewer suggestions for multi-author papers
  39. Optimal timing for lithium levels
  40. Tourette syndrome research highlights from 2021
  41. Tourette syndrome research highlights from 2020
  42. Neurobiology and Functional Anatomy of Tic Disorders
  43. The timing of tics is fractal, even in the first few months of a tic disorder
  44. Tourette syndrome research highlights from 2020
  45. Treatment failure in persistent tic disorders: an expert clinicians’ consensus-based definition
  46. Predicting Clinical Course from Subcortical Shape in Provisional Tic Disorder
  47. Low-Dose Augmentation With Buprenorphine for Treatment-Resistant Depression: A Multisite Randomized Controlled Trial With Multimodal Assessment of Target Engagement
  48. Recent progress on Tourette syndrome
  49. A Comprehensive Review of Tic Disorders in Children
  50. What happens to tic disorders over time?
  51. "I can hold my tics back for a while. What does that tell me?"
  52. TicTimer Web: software for measuring tic suppression remotely
  53. Electronic medical records need to accommodate confidentiality for presymptomatic testing
  54. The Child with Tics or Other Common Movement Disorders
  55. Tourette syndrome research highlights from 2019
  56. Course of tic disorders over the lifespan
  57. Tourette syndrome research highlights from 2019
  58. TicTimer Web: software for measuring tic suppression remotely
  59. Correlates and clinical implications of tic suppressibility
  60. Size of hippocampus predicts improvement in children with recent-onset tics
  61. Phonic tics and one motor tic? Call it Tourette syndrome.
  62. Can we measure Parkinson disease severity with levodopa and MRI?
  63. Age-dependent differences in functional brain networks are atypical in Tourette syndrome
  64. In obesity, pictures of high-calorie food elicit dopamine release equally when hungry or full.
  65. Hippocampal volume in Provisional Tic Disorder predicts tic severity at 12-month follow-up
  66. What happens to children with recent-onset tics, and why?
  67. Dopamine buffering capacity imaging: A pharmacodynamic fMRI method for staging Parkinson disease
  68. 2.54 EXPLORING BEHAVIORAL MARKERS PREDICTING ONE-YEAR TIC OUTCOME IN CHILDREN WITH RECENT-ONSET TICS
  69. Treating depression in epilepsy: a controlled trial
  70. The urge to blink in Tourette syndrome
  71. Tourette syndrome research highlights from 2018
  72. Atypical Functional Connectivity In Tourette Syndrome differs between Children and Adults
  73. Tic Suppression in Children With Recent-Onset Tics Predicts 1-Year Tic Outcome
  74. In Provisional Tic Disorder, better tic suppression predicts better prognosis
  75. Provisional Tic Disorder is not so transient
  76. Correction: Brain structure in pediatric Tourette syndrome
  77. Ziprasidone may have a role in treating psychosis in Parkinsonian disease
  78. The urge to blink in Tourette syndrome
  79. How to switch to pimavanserin from an older antipsychotic for psychosis in Parkinson's disease
  80. Atypical Functional Connectivity in Tourette Syndrome Differs Between Children and Adults
  81. Transient tics aren't: Outcome of recent-onset tic disorder at one year
  82. Testing a new (D1) dopamine blocking strategy to treat Tourette syndrome in children
  83. TicTrainer software
  84. Research on tic disorders from 2017
  85. Effects of DBS in dorsal vs. ventral STN
  86. Who can suppress tics best?
  87. Tourette Syndrome
  88. TicTimer software for measuring tic suppression
  89. TicTrainer web software for tic suppression training
  90. Tourette syndrome research highlights from 2016
  91. Patterns and predictors of tic suppressibility in youth with tic disorders
  92. 4.36 A Randomized, Double-Blind, Placebo-Controlled Study of the D1 Receptor Antagonist Ecopipam for Children and Adolescents With Tourette's Disorder
  93. TicTimer: software for measuring tic suppression
  94. Tourette syndrome research highlights from 2016
  95. Mapping movement, mood, motivation, and mentation in the subthalamic nucleus
  96. A Case of Apparent Upper-Body Freezing in Parkinsonism while Using a Wheelchair
  97. What creates the urge to tic in Tourette syndrome?
  98. Preliminary evidence that negative symptom severity relates to multilocus genetic profile for dopamine signaling capacity and D2 receptor binding in healthy controls and in schizophrenia
  99. Brain structure in pediatric Tourette syndrome
  100. VISIT-TS: A multimedia tool for population studies on tic disorders
  101. A picture is worth 1000 words: a new tool for Tourette studies
  102. Tourette syndrome research highlights 2015
  103. Prediction of striatal D2 receptor binding by DRD2/ANKK1 TaqIA allele status
  104. Sweet Dopamine: Sucrose Preferences Relate Differentially to Striatal D 2 Receptor Binding and Age in Obesity
  105. Brain structure in pediatric Tourette syndrome
  106. When do tics turn into Tourette syndrome?
  107. Return of QuanDyn(TM)
  108. Designing MRI studies of children with neuropsychiatric disorders
  109. Machine learning "diagnosis" of Tourette syndrome by resting brain activity
  110. Correction: Insulin, Central Dopamine D2 Receptors, and Monetary Reward Discounting in Obesity
  111. Safety of i.v. L-DOPA
  112. Automated training to hold still
  113. A review session can raise medical student scores on the psychiatry shelf exam
  114. Impact of a structured review session on medical student psychiatry subject examination performance
  115. Stand up for i.v. levodopa!
  116. Brain imaging in Tourette's, 2014-2015
  117. Safety of i.v. L-DOPA (preprint)
  118. Insulin, Central Dopamine D2 Receptors, and Monetary Reward Discounting in Obesity
  119. Tourette Syndrome research highlights 2014
  120. Brain dopamine pathways influence emotional eating
  121. Rapid quantitative pharmacodynamic imaging with Bayesian estimation
  122. Whole-brain blood flow correction in ASL
  123. Tourette Syndrome research highlights 2014
  124. Kids can suppress tics early on--if the price is right
  125. Levodopa effects on [11C]raclopride binding in the resting human brain
  126. Tics
  127. Arterial spin labeling versus BOLD in direct challenge and drug-task interaction pharmacological fMRI
  128. F1000Research: Tics welcomes you to 21st century biomedical publishing
  129. Intro to special issue on Tourette syndrome
  130. Current anxiety disorder affects mood response to STN DBS in PD
  131. A revised method for measuring distraction by tactile stimulation
  132. Anatomical location in STN matters for DBS in Parkinson's
  133. Insulin, dopamine D2 receptors, and monetary reward discounting: A common pathway for food and drug addiction
  134. Developmental Changes in the Organization of Functional Connections between the Basal Ganglia and Cerebral Cortex
  135. Spatial Reorganization of Putaminal Dopamine D2-Like Receptors in Cranial and Hand Dystonia
  136. Levodopa-stimulated dopamine release in Tourette syndrome
  137. A within-subject comparison of seizure duration with etomidate and methohexital in electroconvulsive therapy
  138. Prolactin and fMRI response to SKF38393 in the baboon
  139. Automatic size and shape measurements of deep brain structures in Tourette syndrome
  140. Rapid quantitative pharmacodynamic imaging by a novel method: theory, simulation testing and proof of principle
  141. Towards objectively quantifying sensory hypersensitivity: a pilot study of the “Ariana effect”
  142. Olanzapine for psychosis in Parkinson disease
  143. Neurobiology and Functional Anatomy of Tic Disorders
  144. A comparison of D2 receptor specific binding in obese and normal‐weight individuals using PET with (N‐[11C]methyl)benperidol
  145. NMB PET outside the striatum
  146. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease
  147. Mood Response to Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease
  148. Prospectively Determined Impact of Type 1 Diabetes on Brain Volume During Development
  149. A New (Old) Treatment Option for Depression in Parkinson's Disease
  150. Clinical Vignettes in Parkinson's Disease: A Collection of Unusual Medication-Induced Hallucinations, Delusions, and Compulsive Behaviours
  151. Dopaminergic Effects on Cortical Function in Tourette's (Levodopa Protocol) (TSfMRI)
  152. A Perfusion MRI Study of Emotional Valence and Arousal in Parkinson’s Disease
  153. Quantification of Indirect Pathway Inhibition by the Adenosine A2a Antagonist SYN115 in Parkinson Disease
  154. Tics
  155. Deep brain stimulation for Tourette syndrome
  156. Hippocampal Volumes in Youth With Type 1 Diabetes
  157. Neuroimaging in Baboons
  158. Cerebral Mitochondrial Metabolism in Early Parkinson's Disease
  159. Motor asymmetry and substantia nigra volume are related to spatial delayed response performance in Parkinson disease
  160. Psychiatric screening for DBS
  161. The Cognitive Correlates of Functional Status: A Review From the Committee on Research of the American Neuropsychiatric Association
  162. Regional Brain Volume Differences Associated With Hyperglycemia and Severe Hypoglycemia in Youth With Type 1 Diabetes
  163. Validity of large-deformation high dimensional brain mapping of the basal ganglia in adults with Tourette syndrome
  164. Intravenous levodopa administration in humans based on a two-compartment kinetic model
  165. The Value of Quantitative Electroencephalography in Clinical Psychiatry: A Report by the Committee on Research of the American Neuropsychiatric Association
  166. Repetitive and impulsive behaviors in treated Parkinson disease
  167. II.P5 Effects of Parkinson Disease (PD) laterality on spatial working memory performance
  168. Sex, Lies, and Neuroimaging
  169. Provisional diagnostic criteria for depression in Parkinson's disease: Report of an NINDS/NIMH Work Group
  170. Brain Stimulation in Psychiatric Treatment
  171. Blood Flow Imaging of the Brain: 50 Years Experience
  172. Levodopa Challenge Neuroimaging of Levodopa-Related Mood Fluctuations in Parkinson's Disease
  173. Pathophysiology of parkinsonism due to hydrocephalus
  174. Dopaminergic modulation of response inhibition: an fMRI study
  175. Cognitive-pharmacologic functional magnetic resonance imaging in tourette syndrome: a pilot study
  176. Atlas Template Images for Nonhuman Primate Neuroimaging: Baboon and Macaque
  177. Asymmetric regional cerebral blood flow in sedated baboons measured by positron emission tomography (PET)
  178. Rapid intravenous loading of levodopa for human research: clinical results
  179. Long term treatment and disease severity change brain responses to levodopa in Parkinson's disease
  180. A possible substrate for dopamine-related changes in mood and behavior: Prefrontal and limbic effects of a D3-preferring dopamine agonist
  181. Psychiatric Neuroimaging Research
  182. Clinical Features and Comorbidity of Mood Fluctuations in Parkinson's Disease
  183. Clinical Features and Comorbidity of Mood Fluctuations in Parkinson's Disease
  184. Template Images for Nonhuman Primate Neuroimaging: 2. Macaque
  185. Template Images for Nonhuman Primate Neuroimaging: 1. Baboon
  186. Dopa-Induced Blood Flow Responses in Nonhuman Primates
  187. Response to levodopa challenge in Tourette syndrome
  188. Neuropsychiatry of movement disorders
  189. On the efficiency of stereologic volumetry as commonly implemented for three-dimensional digital images
  190. Diminished regional cerebral blood flow response to vibration in patients with blepharospasm
  191. Altered thalamic response to levodopa in Parkinson’s patients with dopa-induced dyskinesias
  192. Putamen volume in idiopathic focal dystonia
  193. Preventing contractures in NMS and dystonia
  194. MPTP induces dystonia and parkinsonism
  195. Baboon Basal Ganglia Stereotaxy Using Internal MRI Landmarks: Validation and Application to PET Imaging
  196. Personality disorder scores improve with effective pharmacotherapy of depression
  197. Stereological MRI volumetry of the frontal lobe
  198. A Metric for Testing the Accuracy of Cross-Modality Image Registration: Validation and Application
  199. The Dexamethasone Suppression Test for Diagnosing Depression in Stroke Patients
  200. Anosognosia for Depressive Signs
  201. Diagnosing Depression After Stroke
  202. Platelet Binding Characteristics Distinguish Placebo Responders from Nonresponders in Depression
  203. MRI volumetry of prefrontal cortex
  204. Hippocampal MR volumetry
  205. Severe Imipramine-Induced Myoclonus in a Patient with Psychotic Bipolar Depression, Catatonia, and Schizencephaly
  206. Subcortical brain anatomy in anorexia and bulimia
  207. Faculty of 1000 evaluation for Lifetime prevalence, age of risk, and genetic relationships of comorbid psychiatric disorders in Tourette syndrome.
  208. TicTimer software for measuring tic suppression
  209. “But my department chair wants big-name journals”: Gentle steps to open publishing
  210. Software for web-based tic suppression training
  211. Tics
  212. Treatment of Parkinson’s disease psychosis
  213. Tourette syndrome research highlights from 2016
  214. BillCorrectly: A software tool to help psychiatrists bill E&M codes appropriately
  215. Suggestions for new NIH grant applicants